Immune-mediated adverse rheumatic reactions following administration of immune checkpoint inhibitors
Immunotherapy with immune checkpoint inhibitors (ICIs) opens up new prospects in treatment of malignancies, although this novel therapy quite often results in development of immune-related adverse events (irAEs), which can limit their clinical use. IrAEs can affect almost any organ system, including...
Main Authors: | I. V. Menshikova, V. V. Strogonova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2020-09-01
|
Series: | Научно-практическая ревматология |
Subjects: | |
Online Access: | https://rsp.mediar-press.net/rsp/article/view/2934 |
Similar Items
-
IMMUNE CHECKPOINT INHIBITION AND AUTOIMMUNITY: RHEUMATOLOGICAL PROBLEMS
by: E. L. Nasonov
Published: (2018-03-01) -
Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors
by: Jennifer Kleponis, et al.
Published: (2015-09-01) -
Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors
by: Zhu Y, et al.
Published: (2018-08-01) -
Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition
by: Jared M. Newton, et al.
Published: (2019-08-01) -
Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events
by: Davies M, et al.
Published: (2017-08-01)